Seelos Therapeutics, Inc. (SEELQ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Seelos Therapeutics, Inc. (SEELQ) has a cash flow conversion efficiency ratio of 0.035x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-972.00K) by net assets ($-28.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Seelos Therapeutics, Inc. (SEELQ) defensive interval to measure how many days the company can operate on defensive assets alone.
Seelos Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2020–2023)
This chart illustrates how Seelos Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Seelos Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Seelos Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
European Resources Limited
AU:ERE
|
N/A |
|
Nuvve Holding Corp
NASDAQ:NVVEW
|
2.691x |
|
Innoviz Technologies Ltd
NASDAQ:INVZW
|
-0.153x |
|
Jack Nathan Medical Corp
V:JNH
|
0.214x |
|
Godha Cabcon & Insulation Limited
NSE:GODHA
|
-1.064x |
|
Future Enterprises Limited
NSE:FEL
|
-0.192x |
|
Solartron Public Company Limited
F:TUUF
|
0.037x |
|
Advantage Solutions Inc
NASDAQ:ADVWW
|
0.090x |
Annual Cash Flow Conversion Efficiency for Seelos Therapeutics, Inc. (2020–2023)
The table below shows the annual cash flow conversion efficiency of Seelos Therapeutics, Inc. from 2020 to 2023. For the full company profile with market capitalisation and key ratios, see Seelos Therapeutics, Inc. (SEELQ) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-33.51 Million | $-23.91 Million | 0.714x | -87.71% |
| 2022-12-31 | $-10.61 Million | $-61.60 Million | 5.806x | +779.25% |
| 2021-12-31 | $57.32 Million | $-48.99 Million | -0.855x | +89.49% |
| 2020-12-31 | $2.57 Million | $-20.91 Million | -8.131x | -- |
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therap… Read more